Application of amniotic epithelial cells in pharmacy

A technology of amniotic membrane epithelial cells and uses, applied in the field of biomedicine, can solve problems such as limited clinical application and source problems, and achieve the effects of wide sources, improvement of mobility function, and reduction of cerebral edema symptoms

Active Publication Date: 2010-06-09
SHANGHAI ICELL BIOTECH +5
View PDF6 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The use of stem cells to repair or regenerate damaged brain nerve cells has become a hot spot in the field of neuroscience today. The transplantation of neural stem

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of amniotic epithelial cells in pharmacy
  • Application of amniotic epithelial cells in pharmacy
  • Application of amniotic epithelial cells in pharmacy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Example 1. hAEC isolation and culture

[0043] Take the placenta of healthy caesarean section pregnant women, and strip the amniotic membrane from the chorion. Rinse with PBS to remove blood cells, digest with 0.25% trypsin at 37°C for 30 min, pipette, add RPMI1640 containing 10% FBS to stop the digestion, filter through a 100-mesh sieve, centrifuge at 1,500 rpm, discard the supernatant, and dilute the mixture with 1×10 4 / cm 2 Inoculate in 10cm dish. hAECs were placed in RPMI-1640 (10% FBS, 100 μg / ml streptomycin, 100 U / ml penicillin, 10 ng / ml EGF and 0.3 mg / ml glutamine) at 37°C, 5% CO 2 cultured in a cell culture incubator.

Embodiment 2

[0044] Example 2. Preparation of hAEC cell preparation

[0045] Example 1 hAEC cultured for 24-72 hours, remove the medium, digest the adherent hAEC with 0.25% trypsin and centrifuge, then rinse with 2ml of PBS solution and centrifuge again, resuspend in PBS and adjust the cell concentration to 105 / μl for later use, namely hAECs cell preparations were obtained.

Embodiment 3

[0046] Example 3. hAECs treat cerebral hemorrhage model in rats

[0047] 1 animal

[0048] SPF grade female adult Sprague-Dawley rats were used in the experiment, purchased from Shanghai Slack Experimental Animal Center, weighing 250±10g, reared in a single cage, free to ingest water and food, and lighted to form a day / night cycle of 12h-12h. The experimental animals were divided into control group, operation (cerebral hemorrhage) group and treatment (cell transplantation) group, wherein the operation group and treatment group were divided into post operation and treatment 2d, 3d, 7d, 14d and 28d.

[0049] 2 Research Methods

[0050] (1) Preparation of cerebral hemorrhage model in rats

[0051] Refer to the methods of CrystalL [Crystal L MacLellan, Gergely Silasi, Candice C Poon, et al. Journal of Cerebral Blood Flow & Metabolism, 2007: 1-10] and make improvements. Rats were anesthetized with chloral hydrate (10% chloral hydrate, injected intraperitoneally by 0.3ml / 100g bod...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical field of biomedicine, in particular to application of amniotic epithelial cells in a medicament for treating hemorrhagic cerebral vascular diseases. The invention discloses the application of the amniotic epithelial cells in treating or improving the hemorrhagic cerebral vascular diseases. The amniotic epithelial cells can effectively treat or improve the hemorrhagic cerebral vascular diseases, obviously improve the action function of patients with the hemorrhagic cerebral vascular diseases, and obviously reduce encephaledema symptoms caused by the hemorrhagic cerebral vascular diseases; the treatment do not need match because the amniotic epithelial cells do not express or weakly express MHC; the amniotic epithelial cells also do not express telomerase, and cell proliferation is controlled, so that the transplantation treatment is safe; meanwhile, the amniotic epithelial cells have wide sources, so that the phenomenon of ethic or morality is avoided. Therefore, the amniotic epithelial cells provide a new effective choice for clinically treating or improving the hemorrhagic cerebral vascular diseases in the future.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to the use of amniotic epithelial cells in medicine for treating hemorrhagic cerebrovascular diseases. Background technique [0002] Cerebrovascular disease refers to a group of diseases with cerebral hemorrhagic or ischemic injury symptoms as the main clinical manifestation caused by cerebral blood vessel rupture, bleeding or thrombosis, also known as cerebrovascular accident or stroke, commonly known as cerebral apoplexy. The disease is often seen in the acute attack of middle-aged people, and severe cases may cause disturbance of consciousness and limb paralysis. Cerebrovascular disease can be divided into two categories according to its nature. One is ischemic cerebrovascular disease, which is more common in clinical practice and accounts for about 70% to 80% of all cerebrovascular patients. It is caused by cerebral arteriosclerosis and other reasons. Cerebral artery lumen ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/50A61P9/10
Inventor 郭礼和刘新洪燕龙尚婧瑨庞力
Owner SHANGHAI ICELL BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap